Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Updated Information About the FDA-funded Study on Risk of blood Clots in Women Taking Birth Control Pills Containing Drospirenone
This information reflects FDA's current analysis of data available to FDA concerning this drug. FDA intends to update this sheet when additional information or analyses become available.
FDA is continuing its review of the potential increased risk of blood clots with the use of birth control pills containing drospirenone.
FDA is releasing the final report of the FDA-funded study that evaluated the risk of blood clots in users of several different hormonal birth control products (contraceptives) (Report: Combined Hormonal Contraceptives [CHCs] and the Risk of Cardiovascular Disease Endpoints. Preliminary results of the FDA-funded study were discussed in the previous Drug Safety Communication [DSC]) on September 26, 2011.
FDA's review of the results of this study, specifically those results related to drospirenone-containing birth control pills were scheduled to be, presented and discussed at the joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on December 8, 2011.